Edition:
India

Global Blood Therapeutics Inc (GBT.OQ)

GBT.OQ on NASDAQ Stock Exchange Global Select Market

54.18USD
25 Sep 2020
Change (% chg)

$0.83 (+1.56%)
Prev Close
$53.35
Open
$53.28
Day's High
$54.78
Day's Low
$53.02
Volume
183,381
Avg. Vol
292,744
52-wk High
$87.50
52-wk Low
$39.96

Latest Key Developments (Source: Significant Developments)

GBT Reports Q2 Loss Per Share Of $0.86
Thursday, 6 Aug 2020 

Aug 5 (Reuters) - Global Blood Therapeutics Inc ::GBT REPORTS RECENT BUSINESS PROGRESS AND SECOND QUARTER 2020 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.86.Q2 EARNINGS PER SHARE ESTIMATE $-1.15 -- REFINITIV IBES DATA.GLOBAL BLOOD THERAPEUTICS - PLANS TO SEEK APPROVAL OF OXBRYTA FOR YOUNGER PEDIATRIC PATIENTS IN UNITED STATES AND SEEK APPROVAL OF OXBRYTA IN EUROPE.  Full Article

Gbt Plans To Seek Expanded Labeling For Oxbryta® For Sickle Cell Disease
Tuesday, 9 Jun 2020 

June 8 (Reuters) - Global Blood Therapeutics Inc ::GBT ANNOUNCES PLANS TO SEEK EXPANDED LABELING FOR OXBRYTA® (VOXELOTOR) TO TREAT CHILDREN AGES 4 TO 11 YEARS WITH SICKLE CELL DISEASE.GLOBAL BLOOD THERAPEUTICS INC - NEW DRUG APPLICATION SUBMISSION PLANNED BY MID-2021.GLOBAL BLOOD THERAPEUTICS - TO SUBMIT NDA FOR OXBRYTA FOR TREATMENT OF SCD IN CHILDREN AGES 4 TO 11 YEARS UNDER FDA'S ACCELERATED APPROVAL PATHWAY.  Full Article

GBT Posts Quarterly Loss Per Share Of $1.59
Thursday, 27 Feb 2020 

Feb 26 (Reuters) - Global Blood Therapeutics Inc ::GBT REPORTS RECENT BUSINESS PROGRESS AND FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS.Q4 LOSS PER SHARE $1.59.Q4 EARNINGS PER SHARE ESTIMATE $-1.24 -- REFINITIV IBES DATA.TOTAL PRODUCT SALES, NET FOR Q4 OF 2019 WAS $2.1 MILLION, DRIVEN BY INITIAL SALES OF OXBRYTA.GLOBAL BLOOD THERAPEUTICS- CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES TOTALED $695.0 MILLION AT DEC 31, 2019, COMPARED WITH $591.8 MILLION AT DEC 31, 2018.  Full Article

GBT And Syros Partner To Discover, Develop And Commercialize Novel Therapies For Sickle Cell Disease And Beta Thalassemia
Wednesday, 18 Dec 2019 

Dec 18 (Reuters) - Global Blood Therapeutics Inc ::GBT AND SYROS PARTNER TO DISCOVER, DEVELOP AND COMMERCIALIZE NOVEL THERAPIES FOR SICKLE CELL DISEASE AND BETA THALASSEMIA.GLOBAL BLOOD THERAPEUTICS INC - SYROS TO RECEIVE $20 MILLION UPFRONT, THREE YEARS OF PRECLINICAL RESEARCH FUNDING AND MILESTONE PAYMENTS.GLOBAL BLOOD THERAPEUTICS INC - GBT WILL PAY SYROS $20 MILLION UPFRONT AND FUND UP TO $40 MILLION IN PRECLINICAL RESEARCH FOR AT LEAST 3 YEARS.GLOBAL BLOOD THERAPEUTICS - SYROS WOULD ALSO RECEIVE MID- TO HIGH-SINGLE DIGIT ROYALTIES ON SALES OF PRODUCTS RESULTING FROM COLLABORATION.GLOBAL BLOOD THERAPEUTICS - WILL RECEIVE OPTION TO OBTAIN EXCLUSIVE LICENSE TO DEVELOP, MANUFACTURE AND COMMERCIALIZE PRODUCTS DUE TO COLLABORATION.GLOBAL BLOOD THERAPEUTICS - SHOULD GBT EXERCISE OPTION UNDER DEAL, SYROS COULD GET UP TO $315 MILLION IN MILESTONES PER PRODUCT CANDIDATE, PRODUCT FROM COLLABORATION.GLOBAL BLOOD THERAPEUTICS - SYROS WOULD HAVE OPTION TO CO-PROMOTE FIRST PRODUCT RESULTING FROM COLLABORATION IN U.S..  Full Article

FDA Approves Oxbryta The First Medicine Specifically Targeting The Root Cause Of Sickle Cell Disease
Tuesday, 26 Nov 2019 

Nov 25 (Reuters) - Global Blood Therapeutics Inc ::FDA APPROVES OXBRYTA™ (VOXELOTOR), THE FIRST MEDICINE SPECIFICALLY TARGETING THE ROOT CAUSE OF SICKLE CELL DISEASE.GLOBAL BLOOD THERAPEUTICS INC - OXBRYTA MEDICINE IS EXPECTED TO BE AVAILABLE THROUGH GBT'S SPECIALTY PHARMACY PARTNER NETWORK WITHIN TWO WEEKS.  Full Article

FDA Grants Accelerated Approval Of Oxbryta To Global Blood Therapeutics
Tuesday, 26 Nov 2019 

Nov 25 (Reuters) - Global Blood Therapeutics Inc ::FDA APPROVES NOVEL TREATMENT TO TARGET ABNORMALITY IN SICKLE CELL DISEASE.U.S. FDA - GRANTED ACCELERATED APPROVAL TO OXBRYTA FOR TREATMENT OF SICKLE CELL DISEASE IN ADULTS & PEDIATRIC PATIENTS 12 YRS OF AGE & OLDER.U.S. FDA - GRANTED APPROVAL OF OXBRYTA TO GLOBAL BLOOD THERAPEUTICS.FDA - OXBRYTA ALSO RECEIVED ORPHAN DRUG DESIGNATION.  Full Article

Global Blood Therapeutics Posts Q3 Loss Per Share $1.07
Friday, 8 Nov 2019 

Nov 7 (Reuters) - Global Blood Therapeutics Inc ::GBT REPORTS RECENT BUSINESS PROGRESS AND THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $1.07.Q3 EARNINGS PER SHARE ESTIMATE $-1.05 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $683.1 MILLION AT SEPTEMBER 30, 2019.  Full Article

GBT Announces Results of Post-hoc Analysis of Phase 3 HOPE Study Showing Improvement in Leg Ulcers in Patients with Sickle Cell Disease Treated with Voxelotor
Monday, 21 Oct 2019 

Oct 21 (Reuters) - Global Blood Therapeutics Inc ::ANNOUNCES RESULTS OF POST-HOC ANALYSIS OF PHASE 3 HOPE STUDY SHOWING IMPROVEMENT IN LEG ULCERS IN PATIENTS WITH SICKLE CELL DISEASE TREATED WITH VOXELOTOR.GLOBAL BLOOD THERAPEUTICS - ‍RESULTS OF EXPLORATORY ANALYSIS SUGGEST VOXELOTOR RESOLVED OR REDUCED SEVERITY OF EXISTING LEG ULCERS​.GLOBAL BLOOD THERAPEUTICS - ‍RESULTS OF EXPLORATORY ANALYSIS SUGGEST VOXELOTOR DECREASED INCIDENCE OF NEW LEG ULCERS IN PATIENTS WITH SCD​.  Full Article

GBT Says U.S. Food And Drug Administration Accepts New Drug Application And Priority Review For Voxelotor For The Treatment Of Sickle Cell Disease
Thursday, 5 Sep 2019 

Sept 5 (Reuters) - Global Blood Therapeutics Inc ::GBT ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION ACCEPTANCE OF NEW DRUG APPLICATION AND PRIORITY REVIEW FOR VOXELOTOR FOR THE TREATMENT OF SICKLE CELL DISEASE.GLOBAL BLOOD THERAPEUTICS - FDA GRANTED PRIORITY REVIEW FOR NDA FOR VOXELOTOR & ASSIGNED PDUFA TARGET ACTION DATE OF FEBRUARY 26, 2020.GLOBAL BLOOD THERAPEUTICS-FDA ALSO INDICATED THAT IT IS NOT CURRENTLY PLANNING TO HOLD ADVISORY COMMITTEE MEETING TO DISCUSS APPLICATION FOR VOXELOTOR.  Full Article

Global Blood Therapeutics Prices A $200 Mln Common Stock Public Offering
Wednesday, 26 Jun 2019 

June 26 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS PRICES A $200.0 MILLION COMMON STOCK PUBLIC OFFERING.GLOBAL BLOOD THERAPEUTICS - PRICING OF PUBLIC OFFERING OF 3.4 MILLION SHARES OF ITS COMMON STOCK FOR GROSS PROCEEDS OF APPROXIMATELY $200.0 MILLION.  Full Article

BRIEF-GBT Announces Plans To Seek Regulatory Approval For Oxbryta To Treat Sickle Cell Patients In Europe

* GBT ANNOUNCES PLANS TO SEEK REGULATORY APPROVAL FOR OXBRYTA® (VOXELOTOR) TO TREAT SICKLE CELL PATIENTS IN EUROPE